



US012083209B2

(12) **United States Patent**
Hashimoto et al.

(10) **Patent No.:** **US 12,083,209 B2**
(45) **Date of Patent:** **Sep. 10, 2024**

- (54) **ORAL CARE COMPOSITION**
- (71) Applicant: **SUNSTAR AMERICAS, INC.**,
Schaumburg, IL (US)
- (72) Inventors: **Kana Hashimoto**, Mount Prospect, IL
(US); **Toru Saito**, Buffalo Grove, IL
(US)
- (73) Assignee: **SUNSTAR AMERICAS, INC.**,
Schaumburg, IL (US)
- (*) Notice: Subject to any disclaimer, the term of this
patent is extended or adjusted under 35
U.S.C. 154(b) by 0 days.

(21) Appl. No.: **17/174,698**

(22) Filed: **Feb. 12, 2021**

(65) **Prior Publication Data**
US 2021/0251870 A1 Aug. 19, 2021

Related U.S. Application Data

(60) Provisional application No. 62/978,098, filed on Feb.
18, 2020.

- (51) **Int. Cl.**
A61K 8/49 (2006.01)
A61K 8/44 (2006.01)
A61K 8/73 (2006.01)
A61K 8/92 (2006.01)
A61Q 11/00 (2006.01)

(52) **U.S. Cl.**
CPC *A61K 8/4926* (2013.01); *A61K 8/442*
(2013.01); *A61K 8/731* (2013.01); *A61K 8/922*
(2013.01); *A61Q 11/00* (2013.01); *A61K*
2800/30 (2013.01); *A61K 2800/48* (2013.01)

(58) **Field of Classification Search**
CPC A61K 8/922; A61K 8/731; A61K 8/442;
A61K 8/4926; A61K 2800/30; A61K
2800/48; A61Q 11/00
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,233,288 A	11/1980	Cornell
4,945,087 A	7/1990	Talwar et al.
5,266,306 A	11/1993	Ohtsuki et al.
5,496,558 A	3/1996	Napolitano et al.
5,541,165 A	7/1996	Turgeon
5,560,906 A	10/1996	Scodari et al.
5,658,554 A	8/1997	Fisher et al.
6,066,345 A	5/2000	de Cock
6,117,417 A	9/2000	Wicks et al.
6,159,459 A	12/2000	Hunter et al.
6,177,064 B1	1/2001	de Troostembergh et al.
6,355,229 B1	3/2002	Adamy
6,471,948 B1	10/2002	Adamy et al.
6,579,513 B1	6/2003	Tashjian et al.
6,656,920 B2	12/2003	Fox et al.
6,706,781 B2	3/2004	Rajaiah et al.
6,828,308 B2	12/2004	Mastradonato et al.
7,198,779 B2	4/2007	Pinol et al.

7,501,452 B2	3/2009	Troha et al.
7,879,877 B2	2/2011	Nagamoto et al.
7,910,089 B2	3/2011	Uotani et al.
8,075,924 B2	12/2011	Loewy et al.
8,221,724 B2	7/2012	Hughes et al.
8,287,842 B2	10/2012	Katou et al.
8,367,650 B2	2/2013	Desjonqueres
8,444,958 B2	5/2013	Kamasaka et al.
8,506,937 B2	8/2013	Kho et al.
8,540,970 B2	9/2013	Rodriguez-Vilaboa
8,658,139 B1	2/2014	Cutler
8,858,920 B2	10/2014	Robinson et al.
9,044,466 B2	6/2015	Cohen et al.
9,138,428 B2	9/2015	Cohen et al.
9,149,454 B2	10/2015	Cooper et al.
9,192,565 B2	11/2015	Vogt et al.
9,198,844 B2	12/2015	Brisley
9,241,885 B2	1/2016	Roberge et al.
2002/0168334 A1	11/2002	Jacob et al.
2003/0232858 A1	12/2003	Barker et al.
2004/0170576 A1	9/2004	Grainger et al.
2005/0100601 A1	5/2005	Capps
2005/0244346 A1	11/2005	Nakao et al.
2005/0250821 A1	11/2005	Sewalt et al.
2006/0094643 A1	5/2006	Svirkin et al.
2006/0134011 A1	6/2006	Shanahan
2006/0134020 A1	6/2006	Robinson et al.
2006/0204551 A1	9/2006	Manley et al.
2007/0031561 A1	2/2007	Lakkis et al.

(Continued)

FOREIGN PATENT DOCUMENTS

CN	101778618 A	7/2010
CN	101780016 A	7/2010

(Continued)

OTHER PUBLICATIONS

Takahashi et al., "Feasibility of Emotion Recognition from Breath Gas Information", Proceedings of the 2008 IEEE/ASME International Conference on Advanced Intelligent Mechatronics Jul. 2-5, 2008, Xi'an, China. (Year: 2008).*

Ialenti et al., "Hyaluronic acid inhibits polycation induced cellular responses," Mediators of Inflammation, 1994, vol. 3, Issue 4, pp. 287-289.

Jia et al., "New Formulation of Drug Controlled Release," Chemical Industry Press, 2005, pp. 242-244 (6 pages including translation).

Rölla et al., "Experiments with a toothpaste containing polydimethylsiloxan/triclosan," Scandinavian Journal of Dental Research, 1993, vol. 101, No. 3, pp. 130-132.

(Continued)

Primary Examiner — Lezah Roberts

(74) *Attorney, Agent, or Firm* — Michael Best & Friedrich LLP

(57) **ABSTRACT**

An oral care composition including greater than 0.0% of an antimicrobial agent that is cetylpyridinium chloride (CPC), a cationic surfactant, an emulsifier, and less than 0.5% by weight of a thickener, such as hydroxyethylcellulose.

18 Claims, No Drawings

(56)

References Cited

U.S. PATENT DOCUMENTS

2007/0274929 A1 7/2007 Alexander et al.
 2008/0118446 A1 5/2008 Jablow
 2008/0247972 A1 10/2008 Conceicao
 2008/0317703 A1 12/2008 Kawa et al.
 2009/0068122 A1 3/2009 Pilch et al.
 2009/0081294 A1 3/2009 Gin et al.
 2009/0104128 A1 4/2009 Haley
 2009/0252690 A1 10/2009 Behan et al.
 2009/0253804 A1 10/2009 Marcy et al.
 2010/0022471 A1 1/2010 Hanifl et al.
 2010/0098791 A1 4/2010 Rodriguez-Vilaboa
 2010/0216830 A1 8/2010 Iyoha et al.
 2011/0014136 A1 1/2011 Kohli et al.
 2011/0020417 A1 1/2011 Takeyama et al.
 2011/0104080 A1 5/2011 Salloum et al.
 2011/0104081 A1 5/2011 Scott et al.
 2011/0171342 A1 7/2011 Phillips, III et al.
 2011/0189110 A1 8/2011 Kohli et al.
 2012/0003162 A1 1/2012 Mordas et al.
 2012/0003163 A1 1/2012 Mordas et al.
 2013/0236400 A1 9/2013 Lewus et al.
 2013/0251772 A1 9/2013 Chopra et al.
 2013/0272971 A1 10/2013 Pimenta et al.
 2013/0295041 A1 11/2013 Kawa et al.
 2013/0344011 A1 12/2013 Ramji et al.
 2013/0344120 A1 12/2013 Scott et al.
 2014/0099347 A1 4/2014 Prencipe
 2014/0155457 A1 6/2014 Nho et al.
 2014/0187629 A1 7/2014 Walker et al.
 2014/0271497 A1 9/2014 Morgan
 2014/0286880 A1 9/2014 Vogt et al.
 2015/0030547 A1 1/2015 Liao et al.
 2015/0231060 A1 8/2015 Okay
 2015/0320701 A1 11/2015 Shigeki
 2015/0335549 A1 11/2015 Patel et al.
 2015/0366794 A1 12/2015 Cooper et al.
 2016/0008250 A1 1/2016 Cohen et al.
 2016/0374352 A1 12/2016 Modak et al.

FOREIGN PATENT DOCUMENTS

CN 101999990 A 4/2011
 CN 102639100 A 8/2012
 CN 103154726 A 6/2013
 CN 103385821 A 11/2013
 EA 001191 B1 12/2000
 EP 0413427 A2 2/1991
 EP 2100590 B1 10/2017
 GB 2348370 A 10/2000
 GB 2354709 A 4/2001
 JP H01153620 A 6/1989
 JP H01246214 A 10/1989
 JP H0259513 A 2/1990
 JP H02169514 A 6/1990
 JP H03151317 A 6/1991
 JP H04173728 A 6/1992
 JP H04202121 A 7/1992
 JP H06239723 A 8/1994
 JP H0725734 A 1/1995
 JP H0725735 A 1/1995
 JP H07133222 A 5/1995
 JP H0812542 A 1/1996
 JP H0848622 A 2/1996
 JP H0825863 B2 3/1996
 JP H08217653 A 8/1996
 JP H08259444 A 10/1996
 JP H08268854 A 10/1996
 JP H08268855 A 10/1996
 JP 2603465 B2 4/1997
 JP H0995457 A 4/1997
 JP H1112142 A 1/1999
 JP H1112168 A 1/1999
 JP H1149625 A 2/1999
 JP H1179961 A 3/1999

JP H11116452 A 4/1999
 JP H11209254 A 8/1999
 JP 2000129299 A 5/2000
 JP 2001072562 A 3/2001
 JP 2001247446 A 9/2001
 JP 2001342500 A 12/2001
 JP 2002370956 A 12/2002
 JP 2003034619 A 2/2003
 JP 2003113059 A 4/2003
 JP 2006016309 A 1/2006
 JP 2006151876 A 6/2006
 JP 2006306768 A 11/2006
 JP 2007008843 A 1/2007
 JP 2007084471 A 4/2007
 JP 2008120753 A 5/2008
 JP 2008143870 A 6/2008
 JP 2008156288 A 7/2008
 JP 2009062285 A 3/2009
 JP 2009107989 A 5/2009
 JP 2010143843 A 7/2010
 JP 2011073970 A 4/2011
 JP 2011073996 A 4/2011
 JP 2011132169 A 7/2011
 JP 2011140454 A 7/2011
 JP 2011148706 A 8/2011
 JP 2011153138 A 8/2011
 JP 2011173873 A 9/2011
 JP 2012012303 A 1/2012
 JP 2012111732 A 6/2012
 JP 2012121833 A 6/2012
 JP 2012136504 * 7/2012
 JP 2012158580 A 8/2012
 JP 2012201632 A 10/2012
 JP 2012214402 A 11/2012
 JP 2013035760 A 2/2013
 KR 20000060197 A 10/2000
 KR 20040081936 A 9/2004
 KR 20080049177 A 6/2008
 KR 20110074232 A 6/2011
 KR 20130107397 A 10/2013
 MX 2013007035 A 9/2013
 RU 2009114589 A 12/2010
 RU 2432149 C2 10/2011
 RU 2011117012 A 1/2013
 RU 2486891 C2 7/2013
 SI 910333 4/2003
 WO WO8907932 A1 9/1989
 WO WO9311754 A1 6/1993
 WO WO9418939 A1 9/1994
 WO WO02080946 A1 10/2002
 WO WO03002056 A2 1/2003
 WO WO2004071475 A1 8/2004
 WO WO2005039518 A1 5/2005
 WO WO2007009879 A1 1/2007
 WO WO2007066497 A1 6/2007
 WO WO2007134335 A2 11/2007
 WO WO2008013740 A2 1/2008
 WO WO2009032406 A1 3/2009
 WO WO2009098531 A1 8/2009
 WO WO2009106963 A2 9/2009
 WO WO2009117644 A1 9/2009
 WO WO2009135867 A1 11/2009
 WO WO2010121081 A1 10/2010
 WO WO2012021419 A2 2/2012
 WO WO2013062424 A1 5/2013
 WO WO2013096427 A2 6/2013
 WO WO2014165226 A2 10/2014

OTHER PUBLICATIONS

International Search Report and Written Opinion for Application No. PCT/US2021/017924 dated Apr. 26, 2021 (15 pages).
 Database GNPD Mintel; Nov. 28, 2018, "Regular Mouthwash", XP093122935, Database accession No. 6166865 (3 pages).
 European Patent Office Supplementary Search Report for Application No. 21756589 dated Feb. 12, 2024 (11 pages).

* cited by examiner

1

ORAL CARE COMPOSITION

CROSS-REFERENCE TO RELATED
APPLICATIONS

This application claims the benefit of U.S. Provisional Patent Application No. 62/978,098, filed Feb. 18, 2020, which is incorporated by reference.

FIELD

The present invention relates to a liquid oral care composition such as a mouthwash or mouth spray.

SUMMARY

One embodiment discloses a liquid oral care composition including greater than 0.0% of an antimicrobial agent that is cetylpyridinium chloride (CPC), a cationic surfactant, an emulsifier, and less than 0.5% by weight of a thickener, such as hydroxyethylcellulose.

Another embodiment discloses a liquid oral care composition including 0.01% by weight to 0.4% by weight cetylpyridinium chloride (CPC), 0.005% by weight to 0.05% by weight PCA ethyl cocoyl arginate, 0.05% by weight to 2% by weight PEG-60 hydrogenated castor oil, and less than 0.5% by weight of hydroxyethylcellulose.

Another embodiment discloses a method of treating teeth including applying a liquid oral care composition including greater than 0.0% of an antimicrobial agent that is cetylpyridinium chloride (CPC), a cationic surfactant, an emulsifier, and less than 0.5% by weight of a thickener, such as hydroxyethylcellulose. In another embodiment, the cationic surfactant is PCA ethyl cocoyl arginate and the emulsifier is PEG-60 hydrogenated castor oil. In another embodiment, the composition includes 0.01% by weight to 0.4% by weight CPC, 0.005% by weight to 0.05% by weight PCA ethyl cocoyl arginate, 0.05% by weight to 2% by weight PEG-60 hydrogenated castor oil, and no more than 0.2% by weight hydroxyethylcellulose. In another embodiment, the composition includes 0.02% by weight to 0.1% by weight CPC, 0.005% by weight to 0.02% by weight PCA ethyl cocoyl arginate, 0.1% by weight to 0.5% by weight PEG-60 hydrogenated castor oil, and no more than 0.2% by weight hydroxyethylcellulose. In another embodiment, the composition includes 0.05% by weight to 0.1% by weight CPC, 0.005% by weight to 0.02% by weight PCA ethyl cocoyl arginate, 0.1% by weight to 0.5% by weight PEG-60 hydrogenated castor oil, and 0.1% by weight to 0.2% by weight hydroxyethylcellulose. In some embodiments, the composition is a mouthwash or mouth spray.

DETAILED DESCRIPTION

Dental plaque is formed by adsorption and propagation of harmful intraoral bacteria, such as *Streptococcus mutans* (“*S. mutans*”), *Aggregatibacter actinomycetemcomitans*, *Porphyromonas gingivalis*, *Prevotella intermedia*, and *Treponema denticola* and the like on the surfaces of teeth. Dental plaque is a known cause of dental caries and gingivitis or periodontitis. Therefore, it is important to remove dental plaque and to prevent adhesion of it (plaque control) for oral sanitation.

One embodiment of an oral composition (e.g., a mouthwash or a mouth spray) comprises an antimicrobial agent, a cationic surfactant, an emulsifier, and a thickener. Preferably, the antimicrobial agent is cetylpyridinium chloride

2

(CPC), the cationic surfactant is PCA ethyl cocoyl arginate, the emulsifier is PEG-60 hydrogenated castor oil, and the thickener is hydroxyethylcellulose. The oral care composition may optionally include additional surfactants, soothing or desensitizing agents, flavoring agents, sweetening agents, humectant agents, coloring agents, additional antimicrobial agents, binders or thickening agents, fluoride, preservatives, and water. The oral care composition, however, does not include an anionic surfactant because the anionic molecules of the anionic surfactant reduces the efficacy of CPC.

CPC has positively charged molecules that interact with negatively charged anionic sites on the cell walls of bacteria. Positively charged CPC can also bind to a tooth surface, which is also negatively charged. CPC can bind with and remain on the tooth surface for a long term. CPC can make an antimicrobial veil on the teeth and thereby help to prevent attachment of bacteria and accumulation of biofilm. Accordingly, CPC can help prevent dental plaque and dental caries by attacking bacteria and adsorbing to the oral mucosa or the surfaces of the teeth. However, when CPC is used in a formulation, other components of the formulation can reduce the ability of CPC to act as an antimicrobial agent. First, CPC is positively charged, so other negatively charged material in a formulation (e.g., anionic molecules) can react with the positively charged CPC molecules, which reduces the activity of CPC with bacteria and tooth surfaces thereby reducing the activity of CPC as an antimicrobial agent. Second, CPC also has characteristics of a surfactant. Therefore, CPC can form a micelle with other surfactants in a formulation. The formation of a micelle may interfere with the ability of CPC to attack the bacteria thereby reduce the antimicrobial activity.

The use of the cationic surfactant and the emulsifier in a formulation with CPC increases the antimicrobial effect of CPC in attacking bacteria and preventing dental plaque and dental caries. The cationic surfactant in the formulation competes with CPC to bind to anionic molecules in the formulation. That is, the cationic molecules of the cationic surfactant bind with anionic molecules in the formulation thereby preventing CPC from binding to anionic molecules in formulation. Accordingly, the CPC is free to attack bacteria and adsorb to the oral mucosa and surfaces of teeth. In the preferred embodiment, the cationic surfactant is PCA ethyl cocoyl arginate, which is an amino acid-based cationic surfactant derived from L-arginine, DL-pyrrolidone carboxylic acid and fatty acid. In other or additional embodiments, other suitable cationic surfactant may be used. These may include one or more of quaternary ammonium salts (e.g., benzalkonium chloride, benzethonium chloride, dimethyldioctadecylammonium chloride, dtaryldimethylbenzyl ammonium chloride, stearyltrimethylammonium chloride, cetyltrimethylammonium chloride, lauryltrimethylammonium chloride), bisbiguanides (e.g., chlorhexidine chloride, chlorhexidine acetate, chlorhexidine gluconate, alexidine hydrochloride, alexidine acetate, alexidine gluconate), or N-long-chain acyl basic amino acid lower alkyl esters or the salts thereof (e.g., pyrrolidonecarboxylic acid salt of N-Lauryl L-Arginine ethyl ester, pyrrolidonecarboxylic acid salt of N-Lauryl L-Arginine methyl ester, carboxylic acid salt of N-Palmitoyl L-Lysine methyl ester, hydrochloric acid salt of N-Cocoyl L-Arginine methyl ester, or laurylpyridinium chloride).

Emulsifiers are surfactants and are typically used to help dissolution of oil (e.g., flavor oil) in water. Emulsifiers therefore form a micelle with CPC when used together in a formulation. The structure of the micelle, which is determined based on the structure of the emulsifier (i.e., surfac-

tant), determines the level of CPC inhibition. The structure of the micelle that results from the use of a poly(oxyethylene) hydrogenated castor oil that has an average molar number of ethylene oxide units added of 35 to 100 moles has been shown to be most effective in reducing the level of CPC inhibition. Moreover, in the preferred embodiment, the emulsifier is PEG-60 hydrogenated castor oil.

In addition to making the oral care composition thicker, the thickener in the formulation helps the oral care composition to stay on the gum tissue. The thickener also gives the oral care composition its moisturizing and gentle finish. In a preferred embodiment, the thickener is hydroxyethylcellulose, which is a polymer. Hydroxyethylcellulose is particularly comfortable for users with dry mouth or a generally sensitive mouth. The amount of hydroxyethylcellulose in the formulation is important because too much hydroxyethylcellulose can reduce the antimicrobial activity of CPC. It is believed that less hydroxyethylcellulose in the formulation shows a higher antibacterial effect than higher amounts of hydroxyethylcellulose. Other suitable thickeners may additionally or alternatively be used, such as nonionic polymers (e.g., methylcellulose, hydroxypropyl methylcellulose, hydroxypropylcellulose, crystalline cellulose, microcrystalline cellulose, polyvinylpyrrolidone) or cationic polymers (e.g., cationic guar gum derivatives and cationized xanthan gum).

The CPC is greater than 0.0% by weight, and in some embodiments, the CPC may measure between 0.01% and 0.4% by weight. In some embodiment, the CPC measures 0.02% by weight to 0.1% by weight. In some embodiments, the CPC measures 0.06% by weight to 0.1% by weight. In some embodiments, for example, the CPC may measure 0.05% by weight, 0.075% by weight, or 0.1% by weight. In some embodiments, the PCA ethyl cocoyl arginate measures 0.005% by weight to 0.05% by weight. In some embodiments, the PCA ethyl cocoyl arginate measures 0.005% by weight to 0.02% by weight. In some embodiments, the PCA ethyl cocoyl arginate measures 0.008% by weight to 0.012% by weight. In some embodiments, for example, the PCA ethyl cocoyl arginate may measure 0.005% by weight, 0.01% by weight, or 0.02% by weight. In some embodiments, the PEG-60 hydrogenated castor oil measures 0.05% by weight to 2% by weight. In some embodiments, the PEG-60 hydrogenated castor oil measures 0.1% by weight to 0.5% by weight. In some embodiments, the PEG-60 hydrogenated castor oil measures 0.12% by weight to 0.2% by weight. In some embodiments, for example, the PEG-60 hydrogenated castor oil may measure 0.1% by weight, 0.15% by weight, 0.2% by weight, 0.3% by weight, or 0.5% by weight. In some embodiments, the hydroxyethylcellulose may be less than 0.5% by weight. In some embodiments, the hydroxyethylcellulose may be not more than 0.3% by weight. In some embodiments, the hydroxyethylcellulose may be not more than 0.2% by weight. In some embodiments, for example, the hydroxyethylcellulose may measure 0.1% by weight or 0.2 by weight.

In one embodiment, the CPC may measure 0.01% by weight to 0.4% by weight, the PCA ethyl cocoyl arginate measures 0.005% by weight to 0.05% by weight, the PEG-60 hydrogenated castor oil measures 0.05% by weight to 2% by weight, and the hydroxyethylcellulose measures not more than 0.3% by weight. In another embodiment, the CPC measures 0.02% by weight to 0.1% by weight, the PCA ethyl cocoyl arginate measures 0.005% by weight to 0.02% by weight, the PEG-60 hydrogenated castor oil measures 0.1% by weight to 0.5% by weight, and the hydroxyethylcellulose measures not more than 0.2% by weight. In another embodi-

ment, the CPC measures 0.06% by weight to 0.1% by weight, the PCA ethyl cocoyl arginate measures 0.008% by weight to 0.012% by weight, the PEG-60 hydrogenated castor oil measures 0.12% by weight to 0.2% by weight, and the hydroxyethylcellulose measures not more than 0.2% by weight.

The oral care compositions discussed herein may be prepared by any suitable method.

The results of the following experiments show an antibacterial effect and usability of the various formulations. For each experiment, the antibacterial effect is tested using a first base having an array of wells and a second base having an array of hydroxyapatite coated pegs. In this experiment, the first base included 96 wells and the second base included 96 pegs. Each of the hydroxyapatite coated pegs is positioned within a single well. First, the hydroxyapatite coated pegs are soaked in sterilized saliva for one hour to initiate acquired salivary pellicle formation. Then the hydroxyapatite coated pegs are washed with deionized water for one minute. Thereafter six of the hydroxyapatite coated pegs are soaked in each test sample (disclosed in the tables below) for two minutes. The hydroxyapatite coated pegs are again washed with deionized water for one minute, three times. Then *S mutans* in a brain heart infusion medium (BD) having 5% sucrose is applied to the wells and cultured for 24 hours in aerobic condition at 37.0° C. Finally, each biofilm is dissolved with 200 μ L 1N NaOH. The amount of *S mutans* adsorbed on the hydroxyapatite coated of each peg is measured using UV-vis spectrophotometric optical density at a wavelength of 550 nm (OD_{550}). The OD measurement is converted into a number representing the amount of *S mutans* in the remaining biofilm on the respective peg. Thereafter, an average amount of *S mutans* in the remaining biofilm after being treated with each sample was determined by taking an average of the data points for each of the six pegs used for each sample.

Also, the usability is tested for taste (e.g., bitterness) and texture (e.g., thickness) to evaluate usability. In particular, each of the test samples was subjected to an organoleptic test administered by trained scientists in a blind trial.

Experiment 1

Experiment 1 used the tests above to determine the antibacterial efficacy and usability of two emulsifiers. All concentrations are measured in percent by weight. In particular, Experiment 1 tested whether PEG-40 hydrogenated castor oil or PEG-60 hydrogenated castor oil has better antibacterial effect and usability. As shown in Table 1, below, Sample 2 including PEG-60 hydrogenated castor oil had a greater antimicrobial effect than PEG-40 hydrogenated castor oil because less bacteria resulted. The taste for both was favorable.

TABLE 1

	Sample 1	Sample 2
CPC	0.075	0.075
PEG-40 hydrogenated castor oil	0.15	0
PEG-60 hydrogenated castor oil	0	0.15
PCA ethyl cocoyl arginate	0.01	0.01

5

TABLE 1-continued

	Sample 1	Sample 2
Hydroxyethylcellulose	0.2	0.2
S mutans in the remaining biofilm on the peg (Number of bacteria calculated from the OD)	5.23×10^8	3.18×10^8
Taste	Good	Good

Experiment 2

Experiment 2 used the tests above to determine the antibacterial efficacy and usability of different concentrations of PCA ethyl cocoyl arginate. All concentrations are measured in percent by weight. As shown in Table 2, below, Sample 4 including 0.005% PCA ethyl cocoyl arginate had a greater antimicrobial effect than the samples having other concentrations because less bacteria resulted. Samples 5-8 including 0.01%, 0.02%, 0.05%, and 0.1% PCA ethyl cocoyl arginate, respectively, had a greater antimicrobial effect than Sample 3 having 0.0025% PCA ethyl cocoyl arginate because less bacteria resulted. Sample 8 having 0.1% PCA ethyl cocoyl arginate is not usable, however, because it has a bad or bitter taste.

TABLE 2

	Sample 3	Sample 4	Sample 5	Sample 6	Sample 7	Sample 8
CPC	0.075	0.075	0.075	0.075	0.075	0.075
PEG-60 hydrogenated castor oil	0.15	0.15	0.15	0.15	0.15	0.15
PCA ethyl cocoyl arginate	0.0025	0.005	0.01	0.02	0.05	0.1
Hydroxyethylcellulose	0.2	0.2	0.2	0.2	0.2	0.2
S mutans in the remaining biofilm on the peg (Number of bacteria calculated from the OD)	4.063×10^8	2.88×10^8	3.18×10^8	3.18×10^8	3.18×10^8	3.18×10^8
Taste	Good	Good	Good	Good	Good	Bad (bitter)

Experiment 3

Experiment 3 used the tests above to determine the antibacterial efficacy and usability of different concentrations of hydroxyethylcellulose. All concentrations are measured in percent by weight. As shown in Table 3, below, Sample 10 having a greater amount of hydroxyethylcellulose had a lesser antimicrobial effect than Sample 9 having less hydroxyethylcellulose. Also, Sample 10 was too thick and therefore not conducive for being used as a liquid oral composition.

TABLE 3

	Sample 9	Sample 10
CPC	0.075	0.075
PEG-60 hydrogenated castor oil	0.15	0.15
PCA ethyl cocoyl arginate	0.05	0.05
Hydroxyethylcellulose	0.2	0.5
S mutans in the remaining biofilm on the peg (Number of bacteria calculated from the OD)	2.88×10^8	4.34×10^8
Taste	Good	Bad (too thick)

6

Exemplary combinations of CPC, PCA ethyl cocoyl arginate, PEG-60 hydrogenated castor oil, and hydroxyethylcellulose in a formulation for an oral composition are given in the table below.

TABLE 4

	Combina- tion 1	Combina- tion 2	Combina- tion 3	Combina- tion 4
Cetylpyridinium chloride (CPC)	0.05	0.05	0.05	0.075
PEG-60 hydrogenated castor oil	0.15	0.2	0.3	0.1
PCA ethyl cocoyl arginate	0.01	0.01	0.005	0.02
Hydroxyethylcellulose	0.2	0.1	0.1	0.1

TABLE 5

	Combina- tion 5	Combina- tion 6	Combina- tion 7	Combina- tion 8
Cetylpyridinium chloride (CPC)	0.075	0.075	0.1	0.1
PEG-60 hydrogenated castor oil	0.15	0.2	0.15	0.5

TABLE 5-continued

	Combina- tion 5	Combina- tion 6	Combina- tion 7	Combina- tion 8
PCA ethyl cocoyl arginate	0.01	0.01	0.01	0.02
Hydroxyethylcellulose	0.2	0.2	0.2	0.1

Although the invention has been described in detail with reference to certain preferred embodiments, variations and modifications exist within the scope and spirit of the invention.

What is claimed is:

1. A liquid oral composition comprising:
 - 0.01% by weight to 0.4% by weight of an antimicrobial agent that is cetylpyridinium chloride (CPC);
 - 0.005% by weight to 0.05% by weight of a cationic surfactant that is 2-pyrrolidone-5-carboxylic acid (PCA) ethyl cocoyl arginate;
 - 0.05% by weight to 2% by weight of an emulsifier that is a poly(oxyethylene) hydrogenated castor oil that has an average molar number of ethylene oxide units added of 35 to 100 moles; and

7

0.1% by weight to 0.3% by weight of a thickener that is a non-ionic polymer.

2. The composition of claim 1, wherein the composition includes 0.02% by weight to 0.1% by weight CPC.

3. The composition of claim 1, wherein the composition includes 0.005% by weight to 0.02% by weight PCA ethyl cocoyl arginate.

4. The composition of claim 1, wherein the emulsifier is PEG-60 hydrogenated castor oil.

5. The composition of claim 4, wherein the composition includes 0.1% by weight to 0.5% by weight PEG-60 hydrogenated castor oil.

6. The composition of claim 1, wherein the thickener is hydroxyethylcellulose.

7. The composition of claim 1, wherein the composition includes one or more additional surfactants, soothing agents, desensitizing agents, flavoring agents, sweetening agents, humectant agents, coloring agents, antimicrobial agents, binders, thickening agents, fluoride, preservatives, and water.

8. The composition of claim 1, wherein the composition does not include an anionic surfactant.

9. The composition of claim 1, wherein the composition is a mouthwash or mouth spray.

10. The composition of claim 1, wherein, the emulsifier is PEG-60 hydrogenated castor oil, and the thickener is hydroxyethylcellulose, and wherein the composition includes 0.05% by weight to 0.1% by weight CPC, 0.005% by weight to 0.02% by weight PCA ethyl cocoyl arginate, 0.1% by weight to 0.5% by weight PEG-60 hydrogenated castor oil, and 0.1% by weight to 0.2% by weight hydroxyethylcellulose.

11. A liquid oral composition comprising:

0.01% by weight to 0.4% by weight cetylpyridinium chloride (CPC);

0.005% by weight to 0.05% by weight 2-pyrrolidone-5-carboxylic acid (PCA) ethyl cocoyl arginate;

0.05% by weight to 2% by weight PEG-60 hydrogenated castor oil; and

0.1% by weight to 0.3% by weight of hydroxyethylcellulose.

12. The composition of claim 11, wherein the composition includes 0.02% by weight to 0.1% by weight CPC, 0.005%

8

by weight to 0.02% by weight PCA ethyl cocoyl arginate, and 0.1% by weight to 0.5% by weight PEG-60 hydrogenated castor oil.

13. The composition of claim 11, wherein the composition includes 0.05% by weight to 0.1% by weight CPC, 0.005% by weight to 0.02% by weight PCA ethyl cocoyl arginate, 0.1% by weight to 0.5% by weight PEG-60 hydrogenated castor oil, and 0.1% by weight to 0.2% by weight hydroxyethylcellulose.

14. The composition of claim 11, wherein the composition includes one or more additional surfactants, soothing agents, desensitizing agents, flavoring agents, sweetening agents, humectant agents, coloring agents, antimicrobial agents, binders, thickening agents, fluoride, preservatives, and water.

15. The composition of claim 11, wherein the composition does not include an anionic surfactant.

16. The composition of claim 11, wherein the composition is a mouthwash or mouth spray.

17. A method of treating teeth comprising:

applying a liquid oral composition to an oral cavity, the liquid oral composition including 0.01% by weight to 0.4% by weight of an antimicrobial agent that is cetylpyridinium chloride (CPC);

0.005% by weight to 0.05% by weight of a cationic surfactant that is 2-pyrrolidone-5-carboxylic acid (PCA) ethyl cocoyl arginate;

0.05% by weight to 2% by weight of an emulsifier that is a poly(oxyethylene) hydrogenated castor oil that has an average molar number of ethylene oxide units added of 35 to 100 moles; and

0.1% by weight to 0.3% by weight of a thickener that is a non-ionic polymer.

18. The method of claim 17, wherein the emulsifier is PEG-60 hydrogenated castor oil, and the thickener is hydroxyethylcellulose, and wherein the composition includes 0.05% by weight to 0.1% by weight CPC, 0.005% by weight to 0.02% by weight PCA ethyl cocoyl arginate, 0.1% by weight to 0.5% by weight PEG-60 hydrogenated castor oil, and 0.1% by weight to 0.2% by weight hydroxyethylcellulose.

* * * * *